Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Joins the Hunt for a Coronavirus Vaccine

By Todd Campbell - Jan 29, 2020 at 11:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the largest pharmaceutical companies in the world will leverage its antiviral research program to attack the rapidly spreading illness.

Biopharmaceutical giant Johnson & Johnson (JNJ 0.70%) is mobilizing dozens of scientists to research the genetic code of the Wuhan coronavirus in hopes of developing a vaccine that can stem its spread. If the company is successful on that front, it will be able to leverage its massive global manufacturing capacity to produce hundreds of millions of vaccine doses for use worldwide.

A woman wearing a face mask.

IMAGE SOURCE: GETTY IMAGES.

The rapid spread of the coronavirus has prompted a slate of biopharma companies to begin researching vaccines, but Johnson & Johnson is the biggest to enter the fray. With global annual sales of over $82 billion, it can deploy significant resources in support of its efforts. As of Wednesday morning, the number of confirmed coronavirus cases had topped 6,150, and it had caused at least 132 deaths.

In the short term, Johnson & Johnson's plan includes evaluating existing antiviral medications to see if they're effective against coronavirus. Longer term, the company will bring to bear technologies previously used to develop and manufacture a Zika vaccine and an investigational Ebola vaccine that is currently being used in Rwanda and the Democratic Republic of the Congo. 

Johnson & Johnson's antiviral treatments for HIV could offer the best chance for people who are already infected with coronavirus. So far, J&J has donated 300 boxes of Prezcobix, an HIV medication containing the active ingredients darunavir and cobicistat, to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for evaluation. It also donated 50 boxes to the Chinese Center for Disease Control and Prevention for research purposes. In 2019, Prezcobix sales exceeded $2.1 billion worldwide. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.08 (0.70%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.